MYLUNG Consortium Study Protocol 2

This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.

Inclusion Criteria:Adult subjects (18 years and older) with newly diagnosed early stage, locally advanced or metastatic non-small cell lung cancerEligible for systemic therapy based on the treating provider's assessmentSubjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic diseaseSubjects may be enrolled within 30 days of initiation of systemic therapySigned informed consentExclusion Criteria:Stage IA at the time of enrollmentSubjects with small cell lung cancerSubjects with Unknown primary tumor origin